Kidney Selective AMPK Activators to Treat Polycystic Kiney Disease

肾脏选择性 AMPK 激活剂治疗多囊肾病

基本信息

批准号：
8646478
负责人：
Ken W Batchelor
金额：
$ 41.51万
依托单位：
NOVATARG, INC.
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-16 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8646478
关键词：
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole AVPR2 gene Affinity Animal Model Anions Autosomal Dominant Polycystic Kidney Biguanides Biological Assay Biology Blood Cell Culture Techniques Cell Proliferation Cell membrane Cells Characteristics Chemicals Chronic Clinical Trials Collaborations Collagen Complication Cyst Cystic Fibrosis Transmembrane Conductance Regulator Data Dialysis procedure Diffusion Disease Drug Design Embryo Evaluation Fluids and Secretions Future Growth Human In Vitro Inhibition of Cell Proliferation Innovative Therapy Institutes Kansas Kidney Lactic Acidosis Lead Life Style Ligands Liver Mediating Medical center Metformin Methods Modification Organ Culture Techniques Organic Cation Transporter Outcome POU2F1 gene POU2F2 gene Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Pharmacotherapy Phase Phosphorylation Polycystic Kidney Diseases Polyuria Process Renal Mass Renal function Series Structure-Activity Relationship System Testing Thirst Transplantation Universities Urination Urine V2 Receptors Water analog base cell growth compliance behavior cost design effective therapy experience human FRAP1 protein interest kidney pharmacology novel novel strategies programs public health relevance screening uptake

项目摘要

DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

描述（由申请人提供）：全球大约有1200万人患有常染色体占主导地位多囊性肾脏疾病（ADPKD）。 ADPKD是一种慢性病，没有有效的药物疗法；在美国，透析和移植的成本> 20亿美元。 Novatarg开发了一种新型和肾脏的选择性方法来治疗PKD治疗，预计会产生阻止潜在疾病过程并为PKD患者提供创新疗法的药物。